Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose: The aim of this clinical trail is to evaluate the effectiveness of Zoledronate (Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients with hormone-refractory prostate cancer.
Condition | Intervention | Phase |
---|---|---|
Hormone-Refractory Prostate Cancer |
Drug: Zometa |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | An Evaluation of Estramustine, Docetaxel and Zoledronate in Patients With Hormone-Refractory Adenocarcinoma of the Prostate |
- To assess and compare the effect of zoledronate and docetaxel/estramustine on markers of bone metabolism in patients with hormone-refractory prostate cancer.
- To determine the response rate, duration of response and time to progression for the combination of estramustine, docetaxel and zoledronate in this population.
- To determine if cycling therapy based on PSA response is feasible in patients with hormone refractory prostate cancer.
- To assess the toxicities of this combination.
- To explore the relationship between markers of bone metabolism and evidence of response to therapy.
Estimated Enrollment: | 34 |
Study Start Date: | April 2002 |
Hormone refractory prostate cancer refers to advanced disease in which the patient no longer responds to conventional hormonal treatment. When hormone therapy is no longer successful, chemotherapy is a treatment option. However, current single-agent treatment has shown to have limited benefit. In this clinical trail, investigators are evaluating the effectiveness of Zoledronate(Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients with hormone refractory prostate cancer. Zometa is a bisphosphonate, and may reduce or delay skeletal complications caused by bone metastases. Estramustine and Taxotere are chemotherapy drugs that have shown activity in hormone refractory prostate cancer. Eligible patients will be randomized to receive Estramustine and Docetaxel (Taxotere) in combination with Zometa or Zometa given alone.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
All patients must have a histologic diagnosis of hormone-refractory adenocarcinoma of the prostate, and hormone refractory disease must be demonstrated by the appearance of new lesions on bone or CT scan and/or a rising PSA value. (No evidence of brain metastasis or untreated spinal cord compression.)
Patients on total androgen suppression therapy must undergo nonsteroidal antiandrogen withdrawal and demonstrate a rising PSA 4 weeks after withdrawal from flutamide and 6 weeks after withdrawal from bicalutamide.
Patient must not be undergoing current chemotherapy, biologic therapy, other investigational or alternative anti-cancer directed therapy or radiation therapy.
Prior radiation therapy must have completed more than 4 weeks prior to registration.
Patients may not have received prior taxane-based cytotoxic chemotherapy for hormone refractory disease.
United States, Michigan | |
The University of Michigan Comprehensive Cancer Center | |
Ann Arbor, Michigan, United States, 48109 |
Principal Investigator: | David C. Smith, MD | University of Michigan Cancer Center |
No publications provided
ClinicalTrials.gov Identifier: | NCT00151073 History of Changes |
Other Study ID Numbers: | UMCC 2001-051 |
Study First Received: | September 6, 2005 |
Last Updated: | January 19, 2006 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Michigan:
Zometa Prostate Cancer Metastatic Prostate Cancer |
Additional relevant MeSH terms:
Adenocarcinoma Prostatic Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Genital Diseases, Male Prostatic Diseases Estramustine Docetaxel |
Hormones Zoledronic acid Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Bone Density Conservation Agents |
ClinicalTrials.gov processed this record on October 16, 2012